Published in J Biol Chem on October 23, 2003
Main roads to melanoma. J Transl Med (2009) 1.67
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res (2009) 1.38
Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res (2010) 1.29
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med (2007) 1.21
Small changes huge impact: the role of protein posttranslational modifications in cellular homeostasis and disease. J Amino Acids (2011) 1.12
Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res (2011) 1.04
Murine cathepsin F deficiency causes neuronal lipofuscinosis and late-onset neurological disease. Mol Cell Biol (2006) 1.02
Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide (2008) 1.00
Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res (2013) 0.97
Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin. Proc Natl Acad Sci U S A (2012) 0.90
Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance. Br J Cancer (2008) 0.90
NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J Invest Dermatol (2008) 0.89
The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer (2011) 0.89
Riboflavin ameliorates cisplatin induced toxicities under photoillumination. PLoS One (2012) 0.88
Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst (2009) 0.86
Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening. Pigment Cell Melanoma Res (2012) 0.85
β3-adrenergic receptor activity modulates melanoma cell proliferation and survival through nitric oxide signaling. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.83
Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells. J Pharmacol Exp Ther (2013) 0.82
Expression and significance of factors related to angiogenesis in choroidal melanoma. Int J Ophthalmol (2011) 0.80
Stem cell factor affects tumour progression markers in metastatic melanoma cells. Clin Exp Metastasis (2006) 0.79
Phosphorylated TP63 induces transcription of RPN13, leading to NOS2 protein degradation. J Biol Chem (2010) 0.77
Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin. Oncotarget (2015) 0.77
NOS1 S-nitrosylates PTEN and inhibits autophagy in nasopharyngeal carcinoma cells. Cell Death Discov (2017) 0.75
Riboflavin Arrests Cisplatin-Induced Neurotoxicity by Ameliorating Cellular Damage in Dorsal Root Ganglion Cells. Biomed Res Int (2015) 0.75
Nanobiotechnological Nanocapsules Containing Polyhemoglobin-Tyrosinase: Effects on Murine B16F10 Melanoma Cell Proliferation and Attachment. J Skin Cancer (2012) 0.75
Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy. PLoS One (2015) 0.75
Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet (2011) 2.26
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res (2008) 1.80
Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res (2010) 1.78
Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol (2009) 1.71
The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol (2002) 1.69
mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther (2003) 1.63
Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol (2002) 1.57
Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer (2006) 1.54
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther (2005) 1.53
Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res (2003) 1.53
Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer (2004) 1.47
Loss of MDA-7 expression with progression of melanoma. J Clin Oncol (2002) 1.34
Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res (2010) 1.29
MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. Int Immunopharmacol (2004) 1.26
Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat (2008) 1.22
Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther (2004) 1.20
mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther (2005) 1.20
Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res (2004) 1.12
PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med (2002) 1.11
Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev (2006) 1.10
Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis (2006) 1.09
Polymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol (2013) 1.08
Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer (2008) 1.06
MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther (2003) 1.06
High prevalence of hypothyroidism among patients with cutaneous melanoma. Oncol Rep (2003) 1.06
Association of activated c-Met with NRAS-mutated human melanomas. Int J Cancer (2012) 1.06
Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res (2004) 1.04
Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res (2011) 1.04
Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother (2006) 1.03
The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells. Mol Ther (2004) 1.01
Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics (2006) 1.00
Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One (2012) 1.00
Slug expression during melanoma progression. Am J Pathol (2012) 0.97
Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol (2006) 0.97
Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells. J Leukoc Biol (2005) 0.96
IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells. Melanoma Res (2012) 0.95
Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine (2008) 0.95
Promotion of melanoma growth by the metabolic hormone leptin. Oncol Rep (2010) 0.93
IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes. Exp Dermatol (2010) 0.90
Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res (2014) 0.90
NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J Invest Dermatol (2008) 0.89
Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther (2003) 0.89
The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer (2011) 0.89
Expression of thyrotropin-releasing hormone by human melanoma and nevi. Clin Cancer Res (2004) 0.89
IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Res (2011) 0.89
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther (2008) 0.88
NO news is not necessarily good news in cancer. Curr Cancer Drug Targets (2005) 0.88
Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res (2012) 0.88
Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. J Interferon Cytokine Res (2006) 0.85
A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther (2002) 0.85
Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer (2010) 0.84
Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol (2007) 0.82
Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer (2007) 0.82
The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget (2012) 0.81
WP760, a melanoma selective drug. Cancer Chemother Pharmacol (2006) 0.81
Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy. J Urol (2003) 0.80
Genetic deficiency of complement isoforms C4A or C4B predicts improved survival of metastatic renal cell carcinoma. J Urol (2009) 0.80
Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. Medicine (Baltimore) (2016) 0.79
Challenges of chemosensitivity testing. Clin Cancer Res (2006) 0.79
Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells. Nutr Cancer (2011) 0.77
Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. J Invest Dermatol (2015) 0.77
Tumor suppressor gene-based nanotherapy: from test tube to the clinic. J Drug Deliv (2011) 0.77
Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population. Pigment Cell Melanoma Res (2013) 0.76
Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res (2008) 0.76
4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res (2016) 0.75
Ultraviolet radiation and the slug transcription factor induce proinflammatory and immunomodulatory mediator expression in melanocytes. J Skin Cancer (2012) 0.75
Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression. Melanoma Res (2017) 0.75
Inflammatory IL-1β-driven JNK activation in stage III melanoma. Pigment Cell Melanoma Res (2015) 0.75